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Abstract
The ability to produce transgenic animals through the introduction of exogenous DNA has existed
for many years. However, past methods available to generate transgenic animals, such as
pronuclear microinjection or the use of embryonic stem cells, have either been inefficient or not
available in all animals, bovine included. More recently somatic cell nuclear transfer has provided a
method to create transgenic animals that overcomes many deficiencies present in other methods.
This review summarizes the benefits of using somatic cell nuclear transfer to create bovine
transgenics as well as the possible opportunities this method creates for the future.
Introduction
The bovine species has long been a focus of research due
to its importance in agriculture. Advancements in bovine
reproductive technologies such as artificial insemination,
multiple ovulation and embryo transfer, as well as oocyte
and embryo culture have improved the ability to increase
superior genotypes in the dairy and beef industries [1]. In
combination with these reproductive technologies, the
ability to insert DNA into livestock [2,3] has provided lim-
itless possibilities for agriculture (e.g., inserting genes
affecting milk and beef production) as well as biomedi-
cine (e.g., producing important proteins in milk).
Although there have been major advances in the field of
bovine transgenics since its inception, the full potential of
transgenic cattle has not been realized in part due to the
limitations of commonly used transgenic technologies.
More recently, the success of somatic cell nuclear transfer
has provided a new and faster way to produce transgenic
cattle while circumventing many of the limitations of
other transgenic techniques. This review will focus on
summarizing the recent past and present state of bovine
transgenics and how somatic cell nuclear transfer will
affect the future potential of producing transgenic cattle.
Producing Transgenic Cattle
There are multiple ways to produce a transgenic animal.
Briefly discussed below are the strengths and weaknesses
of the most common ways currently available to make
transgenic animals. The success, or lack thereof, of each
method in creating transgenic cattle is also summarized.
Although there has been limited success using retroviral
vectors [4] and sperm mediated transgenesis [5,6] in cat-
tle, these techniques will not be discussed in this review
due to space limitations.
Pronuclear microinjection
One of the first techniques created to generate a transgenic
animal was pronuclear microinjection or the insertion of
DNA into the pronucleus of a fertilized oocyte. This tech-
nology was first used in the mouse [7] and then trans-
ferred to other animals including livestock [2,3]. The
success of pronuclear injection with respect to transgene
integration ranges from around 3% for mice, rats and rab-
bits to only 1% for cattle, pigs and sheep [8]. In addition
to the poor efficiency of pronuclear microinjection, this
method usually results in a high percentage of mosaics in
which not all cells of the animal contain the transgene.
The time and cost of screening for germline transmission
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in mosaic animals like cattle can be prohibitive to gener-
ating more transgenic animals through breeding. Using
pronuclear injection to create transgenic animals can also
lead to high variability in transgene expression between
animals due to mosaicism as well as chromosomal posi-
tion effects that occur during the random integration of
the transgene [9]. Testing multiple lines of animals for
proper transgene expression is necessary in a pronuclear
microinjection approach to creating transgenic animals.
Microinjection is also limited in that it only allows for the
random addition of exogenous DNA rather than targeting
to specific sites. DNA targeting is necessary in generating
gene knockouts to model human diseases. The success of
pronuclear microinjection is evident in the generation of
many transgenic cattle but its limitations have hindered
the progress of bovine transgenics.
Stem cells
Embryonic stem (ES) cells are used extensively as way to
create transgenic mice. These cells are isolated from the
inner cell mass of a blastocyst and, kept in the right culture
conditions, have the potential to divide endlessly [10].
This immortal-like characteristic allows for easy propaga-
tion and eventual DNA manipulation through the inser-
tion of transgenes. When transgenic ES cells are isolated
and inserted into a growing mouse embryo, they multiply
and contribute to the resulting fetus giving rise to almost
any tissue type. These chimeric animals are then tested for
germline transmission and used to create fully transgenic
animals through breeding strategies. One big advantage of
using ES cells over microinjection is the ability to select for
transgene integration through the use of selectable mark-
ers. This ability ensures the creation of transgenic off-
spring even if they are chimeras. ES cells also allow for the
targeted alteration of DNA by homologous recombina-
tion leading to the creation of gene knockouts [11]. The
ability to easily create gene knockouts has lead to the
mouse being considered one of the best models for
genetic studies.
Due to the success of mouse ES cells, many attempts have
been made to isolate similar cells in other animals with
limited success [12–14]. Success was achieved in cattle
when ES-like cells were isolated from early embryos,
transfected with exogenous DNA, reintroduced into pre-
implantation embryos and shown to contribute to tissues
of the resulting calves [15]. However, genetic modifica-
tion of cattle ES-like cells is not easy due to the culture sys-
tem required to maintain them as undifferentiated ES cells
and their inability to expand clonally in vitro [15]. Unfor-
tunately, even if cattle ES cells were comparable to mouse
ES cells the generation time and maintenance cost of mul-
tiple mosaic animals would be prohibitive to testing for
germline transmission.
Somatic Cell Nuclear Transfer
Due to absence of proven ES cells and the recent advances
in nuclear transfer (NT), current emphasis for creating
bovine transgenics has been placed on somatic cell
nuclear transfer (SCNT). Nuclear transfer is a technique
that can be used to create a genetically identical copy, or a
clone, of an animal. Nuclear transfer commonly involves
the transfer or placement of a donor nucleus into the cyto-
plasm of an enucleated MII oocyte (figure 1). Donor cells
can originate from a wide variety of cell types ranging
from embryonic blastomeres all the way up to adult cells.
Although initial work in NT focused on using embryonic
blastomeres as a donor source [16], the process was ham-
pered by the limited number of cells available in an early
embryo. More recently success in cattle cloning has been
achieved using fetal [17] and adult [18] cells. The ability
to use cells that can be cultured increased the number of
cells available to clone with as well as facilitated the abil-
ity to make transgenic cattle. Transgenes can be intro-
duced into cultured cells that can be used as donor cells
for SCNT (figure 1).
Advantages in using SCNT for bovine transgenics
Somatic cell nuclear transfer has facilitated the ability to
make transgenic animals by circumventing most of the
Somatic Cell Nuclear Transfer with Transgenic Cells Figure 1
Somatic Cell Nuclear Transfer with Transgenic Cells. 
(A) A mature oocyte is enucleated by a glass pipet and a 
transgenic somatic cell (gray striped cell) is transferred under 
the zona pelucida of the oocyte. An electrical pulse is then 
given to fuse the two cell membranes transferring the trans-
genic donor nucleus into the oocyte. (B) Somatic cells are 
transfected with a transgene and appropriate selection is 
used to isolate a clonal population of transgenic somatic cells.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/81
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shortcomings of other transgenic techniques [17]. One of
the first advantages over microinjection is that the sex of
the animal can be predetermined by choosing the donor
material (ie., male or female tissue). For example, the abil-
ity to select the sex of the animal would increase efficiency
and facilitate the manipulation of milk production
through transgenesis [19]. Second, the use of cell culture
to propagate donor cells can lead to almost limitless
number of transgenic cells that can be frozen and stored
for long periods of time. In conjunction with SCNT these
transgenic donor cells can eventually give rise to numer-
ous cloned transgenic animals. Transgene structure and
expression can be tested by molecular techniques, such as
PCR, Southern blot analysis, Fluorescence in situ Hybridi-
zation and Western blot analysis, before initiating NT and
transferring the embryo to a recipient cow with a lengthy
gestation time of 9 months. The proper use of SCNT also
ensures that 100% of animals produced are transgenic
and that every cell of an animal will have the transgene,
thereby saving time and cost associated with recipient ani-
mals. The ability to use a clonal population of transgenic
cells guarantees the same transgene insertion site for each
clone thus decreasing animal to animal variation in trans-
gene expression levels. Further, transgenes can be added
to a specific genetic background. For example, a female
that is above average on milk protein production may be
used as the genetic background (donor somatic cells) in
which the transgene is placed. Lastly, SCNT allows for not
only the addition of DNA at random sites but also tar-
geted insertion of DNA by homologous recombination
which is vital in modulating specific gene expression as
well creating gene knockouts. Gene targeted pigs [20,21]
and sheep [22,23] have been produced using SCNT
techniques.
SCNT can be improved
Although somatic cell nuclear transfer has lead to various
accomplishments and offers many advantages over cur-
rent transgenic techniques available, improvements can
be made to increase future success. First and foremost is
the need to increase overall efficiency. The success rate for
somatic cell nuclear transfer averages between 1–3% in
most animals including cattle [24]. The majority of
embryos are lost during pregnancy with a 60% higher fetal
loss between gestational days 35–60 when compared to
embryos created through in vitro fertilization (IVF) [1]. In
cloned cattle, there is higher perinatal loss than observed
in the general population. These losses are not due to any
one anomaly but rather complications that can range
from increased birth weight, pulmonary abnormalities,
respiratory problems, to metabolic deficiencies [reviewed
in [25]]. It should be noted that these complications were
first observed in blastomere derived NT offspring and
reported by Willadsen and coworkers in 1991[26]. Pla-
cental abnormalities are also common in bovine NT off-
spring clones as first observed in bovine pluripotent cell
NT pregnancies [27]. Term NT placentae often have large
but few placentomes, edema and hydroallantois [28].
Most SCNT calves survive early postnatal development
and seem to be quite normal and fertile [29]. Many stud-
ies have tried to increase NT efficiency and have seen
small differences due to genotype [30], type of donor cell
[31] and stage of donor cell [32] but no one has had
extreme success.
Nuclear Reprogramming
Current research to decrease the number of pregnancy
losses and thus increase the efficiency of NT has recently
focused on understanding nuclear reprogramming.
Nuclear reprogramming can be loosely defined as a set of
epigenetic changes (those not involving a change in DNA
sequence) required for a nucleus to change developmen-
tal fates.
During the NT process the oocyte changes the fate of the
donor nucleus from its original status (e.g., skin, granu-
losa etc.) to that of a zygotic nucleus. Improper nuclear
reprogramming of the donor nucleus in the oocyte is
thought to be the major reason of failure in the cloning
process. In cattle, studies have shown that methylation
[33–35] as well as gene expression [36–38] are abnormal
when compared to in vivo and in vitro matured embryos.
Recently, Enright and coworkers showed that histone
acetylation levels in cells changed with respect to the stage
of cell, cell type and numbers of cell passages suggesting
that histone acetylation could be a factor in improper
nuclear reprogramming in NT [39]. Epigenetic abnormal-
ities caused by the NT process however are not passed on
to the offspring of cloned animals as shown in mice [40].
A recent idea that may increase efficiencies in nuclear
reprogramming during the NT process is the exposure of
donor cells to remodeling factors through in vitro systems
before NT is initiated [41]. The addition of Xenopus laevis
egg extracts was shown to successfully inhibit transcrip-
tion, which has been hypothesized to facilitate nuclear
reprogramming [41]. The addition of roscovitine, which
inhibits cyclin dependent kinase 2, to donor cells success-
fully synchronized donor cell cycle and increased surviva-
bility of cloned calves and thus may increase the nuclear
reprogramming capacity of the donor cells [42]. The addi-
tion of trichostatin A, a histone deacetylase inhibitor, to
donor cells significantly increased blastocyst development
rate compared to non-treated control cells when both
were used for SCNT [43]. Studies such as these give evi-
dence that increasing NT efficiency is possible and will
only improve in the future.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/81
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Cell lifespan
Another difficulty in using SCNT to create transgenic ani-
mals is that unlike ES cells somatic cells have a definitive
lifespan. Bovine fetal fibroblast cells, which are com-
monly used to make transgenic cattle, have 30–50 popu-
lation doublings (PDs) before senescence [44]. Although
Cibelli and coworkers were able to create transgenic calves
from a clonally derived transgenic cell line with a capacity
for 30 PDs [17], Clarke and coworkers have estimated that
gene targeting requires around 45 PDs [45]. Recent evi-
dence has shown that the doubling capacity can vary
widely between cell lines and that genetics may play a
major role in determining this capacity illustrating the
importance of picking the right cell line to work with [46].
Even though there has been some success using late pas-
sage cells for NT [47,48] the extended cell culture neces-
sary for clonal propagation of a transgenic cell most likely
leads to senescence. For example, out of the 25 gene tar-
geted colonies identified by Denning and coworkers 23
senesced before they could be expanded for NT [49].
One approach recently suggested to overcome the prob-
lem of senescence of somatic cells is the introduction of
TERT [50]. TERT is the catalytic component of telomerase
and has been shown to immortalize cell lines when it is
expressed [51]. Even cell lines with active TERT that have
been passaged numerous times show no sign of pheno-
typic or chromosomal abnormalities that are hallmark of
a transformed cell line [52,53]. A reversible system has
been reported, making it possible to express TERT until
genetic modifications are completed and then silencing it
before NT [54]. The future use of such a system would
facilitate transgenic work in primary cell cultures and
improve the chances of deriving SCNT offspring from
these modified donor cells.
Combining transgenics and SCNT
Although SCNT efficiencies can be improved, it is cur-
rently the best method to produce transgenic livestock
[55]. In this study sheep transgenic for human clotting
factor IX were produced by transfecting fetal fibroblast
cells with a transgene containing human clotting factor IX
linked to the β-lactoglobulin gene promoter. The authors
successfully produced transgenic sheep when these cells
were used as donor cells for SCNT. The study also demon-
strated that using SCNT improved overall efficiency 2.5
times over pronuclear microinjection mainly due to the
fewer animals required as recipients. Today, most com-
mercial companies producing transgenic livestock use
SCNT extensively to produce their transgenic founders.
The success of SCNT in creating transgenic livestock has
provided a means for generating gene-targeted animals.
McCreath and coworkers, produced the first gene-targeted
mammal other than mouse when they inserted a trans-
gene into the ovine α1 procollagen locus [22]. Gene tar-
geting success has also been achieved in pigs with the
galactosyltransferase gene in the hopes of providing
organs for organ transfers [20,21,49]. The number of gene
targeting studies will multiply as the amount of genetic
sequence information increases.
Transgenic Cattle produced through SCNT
To date, the focus of studies producing transgenic cattle
through SCNT has ranged from proof of principle [17] to
altering milk protein concentration [19]. The first trans-
genic cattle produced through SCNT were transgenic for a
fusion β-galactosidase-neomycin gene and demonstrated
that cattle could be produced through using transgenic
culture cells for SCNT [17]. Multiple studies have used the
green fluorescent protein (GFP) gene transfected donor
cells and subsequently used for NT to create bovine
embryos and calves. Green fluorescent protein was used
in these studies as a marker for screening preimplantation
embryos, proving germ line transmission and trying to
increase the overall efficiency of the process [48,56–59].
One recent study used SCNT to create calves transgenic for
two casein genes involved in milk protein production
[19]. When the resulting calves were induced to lactate,
the levels of β- and κ-casein protein in milk were altered
suggesting that the transgene did influence milk content.
The ability to generate bovine embryos using transgenic
cells has differed between studies. Some studies have
shown a significant decline in blastocyst development rate
when using transgenic cells compared to nontransgenic
cells for SCNT [56,60]. Other studies however have not
reported a difference in SCNT blastocyst development rate
when using transgenic cells [19,48]. Extended culture
needed for transfection and selection may induce changes
to the donor cells that decrease SCNT efficiency [60]. In
addition, variation in SCNT procedures among labs and
the inherent biological variability within the NT system
(oocyte maturation, cell culture and donor cell lines) can
add another level of variability [61]. A recent study sug-
gested that the coordination of donor cell type and cell
cycle stage is necessary to maximize NT efficiency [62]. For
transfected cells, the G1 stage provided the best blastocyst
development rate while for nontransfected cells the G0
stage provided the best blastocyst development rate when
these cells were used for NT. Further study of factors such
as the specific transgene used, integration site and meth-
odological differences in the NT procedure should also
provide insight into optimizing SCNT with transgenic
cells.
Bovine models for disease
The success of SCNT has provided a means by which the
generation of mammalian animal models other than mice
is now available. The mouse is the usual animal model ofReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/81
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choice due to factors like short generation time, low main-
tenance and cost and ease of availability. Although live-
stock, like pigs and cattle, do not have these attributes that
one might consider as a prerequisite for an animal model,
they do have similarities to humans that may make them
great animal models for human disease. For instance, fac-
tors such as lifespan, size, and possibly genomic organiza-
tion [63,64] are all more similar between cattle and pigs
and humans than compared to mice. Although no one
would dispute the impact that the mouse has had as a
model on understanding human disease, there are dis-
eases like cystic fibrosis in which the mouse does not dis-
play all of the human phenotypes of the disease [65]. Due
to similarities between the lung in sheep and humans,
sheep have been suggested as a possible model for cystic
fibrosis [65]. Similarities between human and livestock
may help advance our understanding of certain diseases
and thus successfully alleviate them.
An example of a human disease in which understanding
may be advanced through the creation of a porcine or
bovine model, and is currently underway in our labora-
tory, is ataxi telangiectasia (A-T). A-T is a genetic disease
with symptoms ranging from neurodegeneration of the
cerebellum to an increased risk of cancer [66,67]. The dis-
ease originates from mutations in the ATM (ataxia tel-
angiectasia mutated) gene that is thought to play a role in
cell cycle control as well as mismatch repair [68–70].
Although mouse models for this disease have displayed
early onset cancer [70–72] they have exhibited only minor
abnormalities in movement [70] and subtle signs of cere-
bellar degeneration [73]. The severe neurodegenerative
phenotype may be absent in mice due to disimilarities in
lifespan, development, and genomic organization when
compared to the human. The longer lifespan, similar ges-
tational length (9 months), and analogous genomic
organization in cattle and humans could provide a better
model for the AT disease. Hopefully the creation of a
bovine or porcine model for A-T will provide insights not
currently available through the mouse and help our
understanding of the disease.
Other possible uses of transgenic cattle generated through 
SCNT
The combination of transgenic technology and SCNT has
made it far easier to make transgenic cattle than in the
past. Building on the initial success of this merger of tech-
nology we hope to see more progress and past ideas real-
ized. The host of possibilities include progress in areas like
agriculture in which it now seems possible to change the
protein content in milk [19] as well as target genes impor-
tant in increasing beef production [74]. In biomedicine,
possibilities include the production of important proteins
in milk such as α-1 antitrypsin for cystic fibrosis, blood
clotting factors like antithrombin III, factor IX and fibrin-
ogen for bleeding disorders, and human serum albumin
which could be useful for treatment of burns [75].
Although such possibilities originated when transgenic
work was started using pronuclear microinjection, hope-
fully these ideas will now be realized through SCNT.
Mentioned briefly throughout this review is the fact that
SCNT provides a way to make targeted modifications to
the genome. This advantage offers even more future pos-
sibilities for transgenic cattle than before. For example,
the inactivation of the bovine PRP gene might provide
bovine spongioform encepholopathy (BSE) resistant cat-
tle. When the PRP gene is knocked out in mice, they are
resistant to scrapie without adverse effects [76]. The
increase in genetic sequence information in cattle will also
provide similar studies such as this one.
Conclusion
Somatic cell nuclear transfer has provided a new way to
create transgenic cattle without the drawbacks of past
transgenic techniques. Although the combination of
transgenic technology and SCNT in cattle is still in its
infancy, the possibilities it provides are almost limitless.
Further research focused on improving our understanding
of nuclear reprogramming will ultimately increase the
efficiency of NT and facilitate the creation of transgenic
SCNT cattle. Improvements in DNA transfection, colony
selection and extending cell lifespan will also increase suc-
cess in creating transgenic, and especially gene targeted,
SCNT bovine. The future possibilities of using artificial
chromosomes as vectors in donor cells [77] and increas-
ing the number of oocytes available for NT through ES cell
differentiation [78] could also boost bovine transgenics.
All of these improvements will facilitate the realization of
goals for transgenic cattle in agriculture and biomedicine.
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